RECRUITING

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Talk to us

Conditions

AgingNADNRnicotinamide ribosideneurovascular couplingendothelial functioncognitive function

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.

Official Title

Effects of NAD Restoration on Neurovascular Coupling in Community Dwelling Older Adults

Quick Facts

Study Start:2023-05-03
Study Completion:2027-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05483465

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥60 and ≤85 years of age
  2. * Adequate hearing and visual acuity to participate in the examinations
  3. * Ability to read and write in English
  4. * Competence to provide informed consent.
  5. * Mini-Mental State Exam score ≥24
  1. * Vision or hearing impairment that would impair the ability to complete study assessments
  2. * Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
  3. * Cerebrovascular accident other than TIA within 60 days prior to Visit 0
  4. * Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse
  5. * Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0
  6. * Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0
  7. * Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.
  8. * Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

Contacts and Locations

Study Contact

Andriy Yabluchanskiy, MD, PhD
CONTACT
405-271-7622
andriy-yabluchanskiy@ouhsc.edu

Principal Investigator

Andriy Yabluchanskiy, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Oklahoma

Study Locations (Sites)

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117
United States

Collaborators and Investigators

Sponsor: University of Oklahoma

  • Andriy Yabluchanskiy, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-03
Study Completion Date2027-12

Study Record Updates

Study Start Date2023-05-03
Study Completion Date2027-12

Terms related to this study

Keywords Provided by Researchers

  • NAD
  • NR
  • nicotinamide riboside
  • neurovascular coupling
  • endothelial function
  • cognitive function

Additional Relevant MeSH Terms

  • Aging